SCHEMBL5651792

SCHEMBL5651792

CC(C)CCNC(=O)c1ccc(OC(=O)N(C)c2ccccc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.59
RAB9A P51151 5/20 0.59
NPC1 O15118 4/20 0.59
ALDH1A1 P00352 2/20 0.58
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
NPSR1 Q6W5P4 1/20 0.54
LMNA P02545 3/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
HPGD P15428 1/20 0.53
HTT P42858 2/20 0.48
MAPT P10636 1/20 0.48
KCNA5 P22460 2/20 0.46
BCHE P06276 1/20 0.45
ACHE P22303 1/20 0.45
CNR2 P34972 1/20 0.45
NAMPT P43490 1/20 0.45
GRM5 P41594 1/20 0.45
LIPE Q05469 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5648430 0.83 SMN1; SMN2 (0.59) SMN1; SMN2RAB9ANPC1ALDH1A1MEN1
SCHEMBL5648352 0.83 RAB9A (0.61) SMN1; SMN2RAB9ANPC1ALDH1A1MEN1
SCHEMBL5648392 0.80 LMNA (0.65) SMN1; SMN2RAB9ANPC1ALDH1A1MEN1
SCHEMBL5649431 0.79 KMT2A (0.50) SMN1; SMN2RAB9ANPC1ALDH1A1MEN1
SCHEMBL5648492 0.79 RAB9A (0.60) SMN1; SMN2RAB9ANPC1ALDH1A1MEN1
SCHEMBL5647591 0.79 SMN1; SMN2 (0.59) SMN1; SMN2RAB9ANPC1ALDH1A1MEN1
SCHEMBL6627789 0.78 SMN1; SMN2 (0.61) SMN1; SMN2RAB9ANPC1ALDH1A1MEN1
SCHEMBL496789 0.77 SMN1; SMN2 (0.81) SMN1; SMN2RAB9ANPC1LMNAL3MBTL1
SCHEMBL5645979 0.77 SMN1; SMN2 (0.63) SMN1; SMN2RAB9ANPC1ALDH1A1MEN1
SCHEMBL27544641 0.76 SMN1; SMN2 (0.79) SMN1; SMN2RAB9ANPC1ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1602191-A Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK AS (DK) 2005-03-30 CN claimed
EP-1458374-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP claimed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US claimed
WO-2003051841-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO claimed
US-7279470-B2 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2007-10-09 US disclosed
CN-1326519-C Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK AS (DK) 2007-07-18 CN disclosed
US-7067517-B2 Use of compounds for decreasing activity of hormone-sensitive lipase NERO NORDISK A/S (DK) 2006-06-27 US disclosed
CN-1602191-A Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK AS (DK) 2005-03-30 CN disclosed
EP-1458375-A2 COMPOSITIONS FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
EP-1458374-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
WO-2003051841-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed
WO-2003051842-A2 COMPOSITIONS DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase LIPE, PNLIP, LPL SMN1; SMN2 4233/4885RAB9A 2926/4885NPC1 814/4885
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive LIPE, PNLIP, LPL SMN1; SMN2 4133/4885RAB9A 3386/4885NPC1 973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.